About a year ago, Tenvie President and Chief Scientific Officer Tony Estrada approached Denali CEO Ryan Watts and others in ...

Tenvie Therapeutics is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug ...

Backed by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, the new company will develop a pipeline of ...

Tenvie Therapeutics has unveiled with $200 million and the goal of transforming the neurological treatment landscape, nabbing ...

Advancing a deep pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseasesLed by expert R&D ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Press Release Tenpoint Therapeutics, Limited ("Tenpoint") and Visus Therapeutics, Inc., ("Visus") announce today the completion of their merger to create an entirely new chapter in ophthalmic ...

The round was led by F-Prime Capital, with participation from Bienville Capital Management and Thayer Ventures. The investment will further TripSuite's mission to enhance the agency and traveler ...

Founded by Wei Wang in 2013, Canoe has now raised a total of $25.0M in total equity funding and is backed by The Carlyle Group, F-Prime Capital, Hamilton Lane, Eight Roads Ventures, and Nasdaq ...

The deal has triggered a crossover financing round with participation from numerous investors, including F-Prime Capital and Sofinnova Partners—both former backers of Tenpoint. The combined ...

A privately held company, Tenpoint Therapeutics is backed by AdBio Partners, British Patient Capital, Eight Roads, EQT Life Sciences, F-Prime Capital, Hillhouse Capital Management, Qiming Venture ...